



# CBH Health, LLC.

CBH Health

## What is CBH Health?

CBH Health is a CNS clinical research system serving individuals with psychiatric illness in the Greater Washington, DC-Baltimore, Maryland area. We are a clinical research organization aiding pharmaceutical companies in the testing of investigational compounds for brain disorders within the adult, geriatric, and pediatric populations.

Drug safety and efficacy are the keys to a successful product launch. CBH Health clinical trials (CBH ClinTrials) provides sponsors with accurate data, rapid enrollment, and high completion rates. CBH ClinTrials believes that the safety and well being of our research volunteers is paramount. CBH Health is committed to providing a safe, supervised environment conducive to volunteer contentment.

### *CBH ClinTrials—Data That Matter*

- **Integrity** CBH Health is committed to providing data which is 100% free of flaws, errors, and omissions. We conduct data collection and management under the highest standard of Good Clinical Practices (GCP) to ensure successful development of compounds for the marketplace. CBH Health is the definition of integrity.
- **Expertise** CBH Health employs a professional, courteous, and expertly trained multidisciplinary staff dedicated to ensuring that the studies performed are accurate and error free.
- **Security** CBH Health is dedicated to maintaining the safety of our volunteers and the security of our sites and the compounds we are researching. We provide a controlled environment where protocol specifications as followed and administered free from outside influence.
- **State-of-the-Art** CBH Health research facilities are widely considered among the most state-of-the-art in the industry. From telemetry, to ECG capabilities, to phlebotomy and sample preparation, to video and recording capabilities of participants, CBH Health is capable of providing our sponsors with the accurate data they require.



## Mission Statement

*CBH Health is committed to providing the community-at-large with options for life improvement through clinical trials research and the development of state-of-the-art pharmacologic treatments.*

### CBH Health, LLC

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850 Phone: 301-251-4702 Fax: 301-762-5711

[www.cbhhealth.com](http://www.cbhhealth.com)

# CBH Health Clinical Trials

## CBH ClinTrials

CBH Health clinical trials (CBH ClinTrials) specializes in all phases (I-IV) of clinical trials of human subjects for pharmaceuticals in development.

**CBH Clinical Research Unit (CRU)** - Our CRU in Rockville, Maryland specializes in Phase I studies, but is capable of conducting I-IV trials. The unit is a fully secured, state-of-the-art, 40-bed facility with expert staffing that can be configured to segregate inpatient volunteers into three distinct zones to allow for the facilitation of three separate simultaneous protocols.

**Fellowship House** - Fellowship House operates as a 16-bed Phase I-IV clinical research site in the Historic Mount Vernon district of Baltimore, Maryland.


Specializing in Central Nervous System disorders, CBH Health has performed over 200 clinical research trials.

### Therapeutic areas in Central Nervous System:

- Schizophrenia Disorder
- Bipolar Disorder
- Major Depressive Disorder
- Alzheimer's Disease
- Anxiety Disorder

Throughout our 15-year experience in conducting clinical trials, sponsors and CROs have entrusted us with a range of study designs and their primary objectives. We have undertaken and successfully completed:

- Single and Multiple Ascending Dose
- Maximum Tolerated Dose
- Dose finding Studies
- Proof of Principle, Proof of Concept
- Pharmacokinetics, Pharmacodynamics
- QT and QTc measurements
- Bioavailability
- Bioequivalence
- Drug-drug Interaction
- Dose Concentration Effect Relationship



Robert E. Litman MD is the Medical Director and Principle Investigator for all clinical trials at CBH Health. He developed his interest in the treatment of schizophrenia at Massachusetts General Hospital, where he completed his residency in Psychiatry. Shortly thereafter, he joined the Experimental Therapeutics Branch, National Institute of Mental Health, NIH, as a Senior Staff Fellow remaining at NIH until 1995, where he continued to pursue his interest in schizophrenia, including investigating the effects of atypical neuroleptics biological and genetic markers in schizophrenia, as well as the development of better combination therapies for schizophrenia using the alpha-2 antagonist idazoxan. After leaving the NIH, he formed his own clinical trials research organization, first in conjunction with area hospitals, and then as a free-standing inpatient and outpatient clinical research organization now known as CBH Health. Since then he has conducted over 200 Phase I-IV clinical trials and has participated in many of the important advances in pharmacotherapy of schizophrenia and other brain disorders. Dr. Litman has an extensive background in psychopharmacology, the evaluation and treatment of schizophrenia, bipolar, major depression, anxiety, and Alzheimer disease. He serves as a consultant in psychopharmacology to many area hospitals and group practices, has over 30 academic publications, and frequently speaks about new advances in the field of psychopharmacology, and on the current issues regarding drug development for psychiatric illness. He is currently an Associate Professor of Psychiatry at Georgetown University Medical School, (where he teaches and trains Psychiatry residents) and a Fellow and Diplomate of the American Board of Psychiatry and Neurology and Diplomate, Added Qualifications in Geriatric Psychiatry.